Oldhoff J M, Knol E F, Laaper-Ertmann M, Bruijnzeel-Koomen C A F M, de Bruin-Weller M S
Department of Dermatology/Allergology, University Medical Centre, Utrecht, the Netherlands.
Allergy. 2006 May;61(5):622-8. doi: 10.1111/j.1398-9995.2006.01075.x.
The atopy patch test (APT) is an in vivo model to study the induction of eczema by inhalant allergens in atopic dermatitis patients. We studied the effect of pretreatment with topical tacrolimus 0.1% on APT in nonlesional skin of patients with atopic dermatitis.
Nonlesional skin of the back of patients with atopic dermatitis (n = 8) was treated once daily for 3 weeks with tacrolimus 0.1% ointment. Cetomacrogol ointment (placebo) was used as a negative control and triamcinolone acetonide 0.1% ointment as positive control. Twenty-four hours after the last APT application, samples were taken from the three treated areas (t = 0 and 24 h) for immunohistochemical analysis.
Pretreatment with tacrolimus ointment did not suppress nonlesional skin infiltrate, in contrast to triamcinolone acetonide. Furthermore, tacrolimus did not inhibit the induction of the APT macroscopically (t = 24 h). An equal influx of T cells, eosinophils, dendritic cells, CD64+ and Fc epsilon RI-positive cells was present compared with placebo. Only CD36+ and CD68-positive cells were inhibited compared with placebo. All cell types were significantly inhibited in triamcinolone acetonide-treated sites compared with placebo.
Pretreatment with tacrolimus 0.1% ointment does not inhibit the APT reaction in patients with atopic dermatitis.
特应性皮炎斑贴试验（APT）是一种体内模型，用于研究特应性皮炎患者吸入性变应原诱发湿疹的情况。我们研究了0.1%他克莫司局部预处理对特应性皮炎患者非皮损皮肤APT的影响。
对8例特应性皮炎患者背部的非皮损皮肤，每日使用一次0.1%他克莫司软膏，持续3周。西托溴铵软膏（安慰剂）用作阴性对照，0.1%曲安奈德软膏用作阳性对照。在最后一次进行APT后24小时，从三个治疗区域（t = 0和24小时）采集样本进行免疫组织化学分析。
与曲安奈德不同，他克莫司软膏预处理并未抑制非皮损皮肤浸润。此外，他克莫司在宏观上未抑制APT的诱发（t = 24小时）。与安慰剂相比，T细胞、嗜酸性粒细胞、树突状细胞、CD64+和FcεRI阳性细胞的流入量相同。与安慰剂相比，仅CD36+和CD68阳性细胞受到抑制。与安慰剂相比，曲安奈德治疗部位的所有细胞类型均受到显著抑制。
0.1%他克莫司软膏预处理不会抑制特应性皮炎患者的APT反应。
